Janet Woodcock, MD, acting commissioner of the FDA, said the agency is meeting with biosimilar developers for biosimilars for 46 reference products.
Janet Woodcock, MD, acting commissioner of the FDA, delivered an upbeat report on biosimilars and generics progress as keynote speaker of the Association for Accessible Medicines’ GRx+Biosims annual conference this week.
She addressed the HHS recommendations for pricing reforms in the drug industry, noting that many patients are not adhering to their medications because of high prices, and also said that, now that COVID-19 pandemic is more under control, the FDA is returning to business as usual, addressing applications for biosimilar and generic approvals and conducting domestic factory inspections, at least, in a normal fashion.
“Now, I am pleased to say that as of July we began resuming normal operations for domestic inspections,” Woodcock said.
“While our agency does not play a direct role in drug pricing, we can, by encouraging development of lower-cost generic and biosimilar products, support competition in the health care market,” she said.
“The savings impact to Americans as a result of the lower costs of these generic and biosimilar products is enormous. In fact, last year, Americans saved $338 billion by using generics and biosimilars, and that’s an increase of $18 million from 2019,” she said.
“In the biosimilar space, new launches and improved utilization led biosimilar savings last year to grow more than 3 times the $2.5 billion saved in 2019, with an especially high impact in oncology,” she said.
Woodcock reported success at the FDA in adjusting user fees for generic and biosimilar application reviews. The user fees help to ensure that the FDA has sufficient funds for conducting these reviews for approval.
She said the FDA is working closely with industry on ways to “maximize scientific and regulatory clarity and ways to enhance efficiency in the review process. We are nearing the completion of that process, as well.”
The agency is sometimes criticized for requiring forms of evidence for drug approval that appear redundant or outdated in the face of modern methods for analyzing and determining safety and efficacy of agents. Use of outdated methods can add significantly to the cost of bringing drugs to market.
The COVID-19 pandemic has represented serious obstacles to the smooth functioning of the FDA because of the drain on its resources; however, Woodcock said “We’ve maintained FDA standards in evaluating products based on high quality data and sound science, and largely continued to meet our…commitments for reviewing applications in a timely manner.”
The agency has approved or tentatively approved hundreds of abbreviated new drug applications in fiscal 2021 alone, and this year the FDA achieved 2 firsts when it approved the first interchangeable biosimilar monoclonal antibody and the first insulin biosimilar, she noted.
“We have now approved 31 biosimilars for 11 different reference products, and the future looks even brighter with interest continuing to grow. As of October 1, 2021, 94 biosimilar development programs were underway, and the FDA has received meeting requests from companies for the development of biosimilars for 46 different reference products,” Woodcock said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.